

25th Global

DIABETES SUMMIT AND MEDICARE EXPO

December 04-05, 2017 Dubai, UAE

Usage and satisfaction of SoloSTAR® among type-2 diabetic patients in Pakistan

Fouzia Moyeen¹ and Junaid Nabee²

¹Ikram Medical Centre, Pakistan

²Sanofi-Aventis Pakistan Limited, Pakistan

Introductio & Aim: SoloSTAR® is a disposable insulin injection pen. This study captured the satisfaction and usage of SoloSTAR® pen by type-2 diabetes mellitus (T2DM) patients in Pakistan.

Methods: This observational study conducted from December 2014 to September 2015 involved 30 sites from 5 cities. First ten Adults T2DM patients (≥18 years) to whom physician decided to prescribe Lantus or Apidra SoloSTAR were enrolled. A questionnaire was administered at baseline and Visit 2 (3±1 month). Satisfaction was measured at visit 2 based on three parameters: overall, technical and social satisfaction.

Results: 295 patients were enrolled in the trial. Their mean age was 52.1 (±9.8) years duration of diabetes was 9.1 (±5.9) years. 54.2% were females. The most common impairment reported was visual (19.7%), hearing (2.7%) and impaired manual dexterity (2.7%). At follow-up, 241 patients returned at 3 (±1) months. 54.8% patients were insulin naive. SoloSTAR® was assessed as satisfactory by 90% of patients whereas 99% patients rated the device as Excellent, Good or Acceptable for technical and social parameters. All 10 and 12 patients with hearing and manual dexterity impairment and of those visually impaired 92% (35/38) patients reported being very satisfied or satisfied with the device. The mean dose of insulin glargine and insulin glulisine was increased from 20.7 U to 24.7 U (<0.01) and 29.6U to 35.8 U (0.002), respectively. Three adverse events; hypoglycemia, lump formation and burning sensation at injection site were reported in three patients. No product technical complaint was received.

Conclusion: This study showed that SoloSTAR® pen was well accepted in urban T2DM patient population in Pakistan. It was perceived by patients to be easy to use and was associated with high levels of user satisfaction by T2DM patients.

Biography

Fouzia Moyeen has completed her Fellowship in Diabetes Management and Training from Diabetes Management and Training Inc. Arizona, USA, followed by Master of Science in Diabetes from University of Warwick, UK. She has a rich clinical experience of working in Pakistan and Saudi Arabia, currently working in a private diabetes care set-up. She is also the pioneer of insulin pumps trainings in Pakistan. She has actively participated in multiple clinical trials and publications in international peer-reviewed journals.

beena.ali@sanofi.com

Notes: